TNFRSF17 and plasma cell myeloma: The clinical studies have identified several numbers of target antigens expressed on abnormal plasma cells in multiple myeloma, including CD19, CD38, CD138, SLAMF7, kappa light chain, B cell maturation antigen (BCMA), and SLAMF7.